Halozyme wins injunction stopping manufacture and sale of Merck's Keytruda SC in multiple European markets
HALO•A court ordered MSD BV to stop manufacturing and selling Merck's Keytruda SC in eight European countries and rejected arguments that Halozyme's EP622 patent is invalid. The intravenous version remains available and is not covered by the patent or injunction.
1. Court injunction
The court ordered MSD BV to stop manufacturing and selling Keytruda SC in eight European countries, and barred it from facilitating infringement by affiliates. It rejected Merck's arguments that Halozyme's EP622 patent is invalid. Keytruda's intravenous version remains available and is not covered by the patent or injunction.
